Gadoterate meglumine

Gadoterate meglumine is a paramagnetic macrocyclic ionic contrast agent administered for magnetic resonance imaging. The chemical name for gadoterate meglumine is D-glucitol, 1-deoxy-1-(methylamino)-, [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceto(4-)-.kappa.N1, .kappa.N4, .kappa.N7, .kappa.N10, .kappa.O1,.kappa.O4, .kappa.O7, .kappa.O10]gadolinate(1-)(1:1);It is indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or anormal vascularity.

Brands
Adult Dose
Neonatal
Paedriatic
Dose: 0 to 0.2 mL/kg
Single Dose: 0.1 (0.1)
Frequency: As recommended.
Route: IV
Instructions: at a flow rate of 1-2mL/sec for paediatrics patients
Characteristics
. It is of Synthetic origin and belongs to Gadoterate meglumine. It belongs to Radiopaque Agents pharmacological group on the basis of mechanism of action. The Molecular Weight of Gadoterate meglumine is 753.90.
Contraindications
Gadoterate meglumine
Effects
The symptomatic adverse reactions produced by Gadoterate meglumine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, injection site pain, Buring Secration, injection site coldness.
Indications
Gadoterate meglumine is primarily indicated in conditions like Radiological contrast agent.
Interactions
No data regarding the interactions of Gadoterate meglumine was found.
Interfrence
Risks
Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
injection Store Below 30°C. Do not Freeze.
Warnings
Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs. Higher than recommended dosing or repeat dosing appear to increase the risk. €¢ Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred. Monitor patients closely for need of emergency cardiorespiratory support
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.